Literature DB >> 20087652

The contralateral synchronous breast carcinoma: a comparison of histology, localization, and magnetic resonance imaging characteristics with the primary index cancer.

Diane M Renz1, Joachim Böttcher, Pascal A T Baltzer, Matthias Dietzel, Tibor Vag, Mieczyslaw Gajda, Oumar Camara, Ingo B Runnebaum, Werner A Kaiser.   

Abstract

Women with unilateral breast carcinoma reveal an increased risk of suffering from malignancies in the contralateral breast. There is a controversy about the existence of bilateral phenotypic similarities. The aim of this investigation was to compare histologic findings, magnetic resonance imaging (MRI) parameters, and tumor localizations of synchronous bilateral carcinomas. MRI revealed in 42 of 875 women (4.8%) with primary index carcinomas a contralateral malignancy. Twenty-two of the 42 contralateral carcinomas could only be detected by MRI, not by clinical examination, X-ray mammography, or ultrasonography. In 875 patients, MRI therefore identified 22 (2.5%) otherwise occult contralateral cancers. To evaluate bilateral MRI similarities, multiple dynamic and morphologic parameters were evaluated. Of 42 bilateral cancer pairs, histologic tumor type was identical in 54.8% (correlation analysis, P < 0.05). Estrogen receptor status was simultaneously positive or negative in 86.2% (P < 0.01), progesterone receptor status in 79.3% (P < 0.05), expression of human epidermal growth factor receptor 2 in 76.2% (P < 0.05). In 75.8%, initial signal increase, and in 63.6%, postinitial curve types were bilaterally congruent on MRI (P < 0.05). Detected masses showed bilaterally similar T2-signal intensity in 81.8% (P < 0.001). Similar shape and margin of tumor masses and occurrence of non-mass-like enhancement were also frequently observed in both breasts (P < 0.05). The main tumor quadrant was the same in 61.9%, the main localization (retromamillar, central, or dorsal) in 66.7% (P < 0.01). Contralateral carcinomas frequently present similar histologic findings, tumor localizations and MRI characteristics reflecting analogies of tumor neoangiogenesis, histopathologic components, and infiltration in the surrounding stroma. Bilateral synchronous carcinomas may represent on each site distinct, but similar biologic entities, due to analogous influences of tumor developments.

Entities:  

Mesh:

Year:  2010        PMID: 20087652     DOI: 10.1007/s10549-009-0718-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Synchronous Bilateral Breast Cancers.

Authors:  Naveen Padmanabhan; Annapurneswari Subramanyan; Selvi Radhakrishna
Journal:  J Clin Diagn Res       Date:  2015-09-01

2.  Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer.

Authors:  Shuning Ding; Xi Sun; Shuangshuang Lu; Zheng Wang; Xiaosong Chen; Kunwei Shen
Journal:  Breast       Date:  2021-03-20       Impact factor: 4.380

3.  Impact of pre-operative breast magnetic resonance imaging on contralateral synchronous and metachronous breast cancer detection-A case control comparison study with 1468 primary operable breast cancer patients with mean follow-up of 102 months.

Authors:  Wen-Pei Wu; Chih-Yu Chen; Chih-Wei Lee; Hwa-Koon Wu; Shou-Tung Chen; Yu-Ting Wu; Ying-Jen Lin; Dar-Ren Chen; Shou-Jen Kuo; Hung-Wen Lai
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

4.  Clinicopathological Characteristics, Treatment and Outcome of 123 Patients with Synchronous or Metachronous Bilateral Breast Cancer in a Swiss Institutional Retrospective Series.

Authors:  Alexandre Huber; Stéphanie J Seidler; Daniela E Huber
Journal:  Eur J Breast Health       Date:  2020-04-01

5.  Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature.

Authors:  Ambrogio P Londero; Sergio Bernardi; Serena Bertozzi; Vito Angione; Giuliana Gentile; Cinzia Dri; Antonio Minucci; Filippo Caponnetto; Roberto Petri
Journal:  Biomed Res Int       Date:  2014-04-27       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.